1	Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled
2	trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's
3	disease (BenfoTeam)
4	Howard H. Feldman ^{1,2,3} ¶*, José A. Luchsinger ⁴ ¶, Gabriel C. Léger ^{1,2} , Curtis Taylor ^{1,2} , Diane M.
5	Jacobs ^{1,2,3} , David P. Salmon ^{1,2,3} , Steven D. Edland ^{1,2,3} , Karen Messer ^{1,2} , Carolyn Revta ^{1,2} , Sarah
6	A. Flowers ⁵ , Kerry S. Jones ⁶ , Albert Koulman ⁶ , Kevin E. Yarasheski ⁷ , Philip B. Verghese ⁷ ,
7	Venky Venkatesh ⁷ , Henrik Zetterberg ⁸⁻¹³ , January Durant ^{1,2} , Jody-Lynn Lupo ^{1,2} , and Gary E.
8	Gibson ¹⁴ [¶] for the ADCS BenfoTeam Study Group [^]
9	
10 11	¹ Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
12 13	² Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla, California, United States of America
14 15	³ Shiley-Marcos Alzheimer's Disease Research Center, La Jolla, California, United States of America
16	⁴ Columbia University Irving Medical Center, New York, New York, United States of America
17	⁵ University of Virginia, Charlottesville, Virginia, United States of America
18 19	⁶ Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
20	⁷ C ₂ N Diagnostics, St. Louis, Missouri, United States of America
21 22	⁸ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
23	⁹ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
24 25	¹⁰ Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
26	¹¹ UK Dementia Research Institute at UCL, London, UK
27	¹² Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
28 29	¹³ Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA

2

30

¹⁴Burke Neurological Institute, Weill Cornell Medicine, White Plains, New York, United States
 of America

- 33
- 34 *Corresponding author
- 35 E-mail: <u>howardfeldman@health.ucsd.edu</u> (HF)
- 36
- ³⁷ [¶]These authors contributed equally to this work.
- [^]Membership of the ADCS BenfoTeam Study Group is provided in the Acknowledgements.

39 Abstract

40 **Background:** Benfotiamine provides an important novel therapeutic direction in Alzheimer's

41 disease (AD) with possible additive or synergistic effects to amyloid targeting therapeutic

42 approaches.

43 **Objective:** To conduct a seamless phase 2A-2B proof of concept trial investigating tolerability,

safety, and efficacy of benfotiamine, a prodrug of thiamine, as a first-in-class small molecule

45 oral treatment for early AD.

46 **Methods:** This is the protocol for a randomized, double-blind, placebo-controlled 72-week

47 clinical trial of benfotiamine in 406 participants with early AD. Phase 2A determines the highest

48 safe and well-tolerated dose of benfotiamine to be carried forward to phase 2B. During phase

49 2A, real-time monitoring of pre-defined safety stopping criteria in the first approximately 150

50 enrollees will help determine which dose (600 mg or 1200 mg) will be carried forward into phase

51 2B. The phase 2A primary analysis will test whether the rate of tolerability events (TEs) is

52 unacceptably high in the high-dose arm compared to placebo. The primary safety endpoint in

53 phase 2A is the rate of TEs compared between active and placebo arms, at each dose. The

- 54 completion of phase 2A will seamlessly transition to phase 2B without pausing or stopping the
- trial. Phase 2B will assess efficacy and longer-term safety of benfotiamine in a larger group of

3

56	participants through 72 weeks of treatment, at the selected dose. The co-primary efficacy
57	endpoints in phase 2B are CDR-Sum of Boxes and ADAS-Cog13. Secondary endpoints include
58	safety and tolerability measures; pharmacokinetic measures of thiamine and its esters,
59	erythrocyte transketolase activity as blood markers of efficacy of drug delivery; ADCS-ADL-
60	MCI; and MoCA.
61	Conclusion: The BenfoTeam trial utilizes an innovative seamless phase 2A-2B design to
62	achieve proof of concept. It includes an adaptive dose decision rule, thus optimizing exposure to
63	the highest and best-tolerated dose.
64	Trial Registration: ClinicalTrials.gov identifier: NCT06223360, registered on January 25,
65	2024.

66 Introduction

Alzheimer's disease (AD) is a progressive age-associated neurodegenerative disease. It 67 is the most common cause of dementia and has devastating socioeconomic implications. More 68 69 than 5 million people are afflicted with AD and related dementias in the United States, and by 70 2050 this number could rise as high as 16 million, with annual costs of over \$1 trillion [1]. The potential to preserve, or even improve, cognition in adults at high risk of cognitive decline due to 71 72 AD clearly has important implications, not only for the affected individual, but also for the support system that bears the social and financial burdens of long-term caregiving. Despite 73 74 recent advances in amyloid targeting therapies, they do not address processes that are upstream 75 and downstream of the amyloid cascade. Thus, complementary therapies that address these processes are needed. 76

BenfoTeam study protocol

4

77	Benfotiamine a prodrug of thiamine provides a novel therapeutic direction in AD that has
78	potential for additive or synergistic effects beyond current mainstream approaches. It is a first-in-
79	class small molecule with a unique mechanism of action, that raises blood thiamine (vitamin B1)
80	50-100 times to pharmacological levels. In this way, it addresses and treats a well-characterized
81	tissue thiamine action deficiency in AD that is associated with changes in glucose metabolism
82	and thiamine dependent post-translational modifications that are linked to AD pathology. This
83	includes action on the α -Ketoglutarate Dehydrogenase Complex (KGDHC)-regulated
84	succinvlation of the TCA cycle that links brain glucose metabolism to AD pathophysiology [2].
85	These related post translational modifications have been identified on tau and Abeta with effects
86	that have been shown to promote plaque and tangle formation [3], neuroinflammation [4, 5],
87	neurodegeneration [2], and increased advanced glycation end products (AGE) [6] which are
88	regulated by thiamine. AGE are toxic modifications that form by the chemical addition of
89	glucose and its byproducts to proteins, lipids and nucleotides when glucose is not tightly
90	controlled in the cell, as is seen with the abnormal glucose metabolism in AD. High
91	concentrations of AGE are predictive of long-term decline in cognition-related daily living
92	performance in patients with AD [7]. Whereas thiamine deficiency increases AGE, increasing
93	brain thiamine activates transketolase, which diminishes AGE [8, 9].
94	CNS thiamine deficiency and its effects on memory and cognition have been well known
95	since 1930s [10]. It is the cause of the amnestic disorder of the Wernicke-Korsakoff syndrome
96	[10] with data strongly supporting its pathogenetic role as well in AD. Thiamine dependent
97	processes are deficient in autopsied brains from AD patients including transketolase (controls the
98	pentose phosphate pathway), the pyruvate dehydrogenase complex [PDHC, links glycolysis to
99	the tricarboxylic acid cycle (TCA)], glyoxalase (detoxification of AGE precursors) and KGDHC

BenfoTeam study protocol

5

(controls the TCA cycle) [11, 12]. Furthermore, the reduced thiamine dependent enzyme activity
measured in post-mortem brain tissue in AD patients, correlates with pre-mortem degree of
impairment on the Clinical Dementia Rating (CDR) score [13]. Preclinical studies using a range
of models including isolated proteins, cell systems and animal models demonstrate that thiamine
deficiency stimulates many AD-like pathological changes including amyloid plaque and tangle
formation, neuronal loss, inflammation, oxidative stress, cholinergic deficits, abnormally reduced
glucose metabolism and memory deficits [14].

107 Recent data provides a mechanistic framework for the decline in thiamine-dependent 108 processes in the brains of patients with AD. Thiamine entry into the brain is controlled by 109 transporters and the transporters are diminished in autopsied brains from AD patients and in 110 brains from mouse models of AD [15]. High concentrations of thiamine in the serum such as 111 those induced by benfotiamine can overcome a reduction in transporters [16]. Model systems 112 studies have demonstrated that high thiamine achieved by increasing dosages of benfotiamine reverses AD-like changes including restoring thiamine-dependent enzymes, with improvement in 113 114 brain glucose metabolism, in reducing plaques [17] and tangles [3], neuroinflammation [4, 5] neurodegeneration [2], and reducing AGE [6]. 115

These preclinical studies have supported a small, single-site 12-month pilot trial of benfotiamine in persons with early AD (35 per treatment arm) that demonstrated benfotiamine is safe and well tolerated with encouraging PK and PD responses [6]. The treatment delivery of benfotiamine in a dose of 600 mg/d achieved its intended PK outcome with a 161-fold mean increase in blood thiamine. The trial also provided preliminary evidence of efficacy of benfotiamine on cognitive and functional outcomes. While group difference in change on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) did not reach statistical

BenfoTeam study protocol

6

123	significance, there was a numerical benefit, with 43% less decline in benfotiamine (-1.39) vs
124	placebo (-3.26) (mixed effect model $p = 0.071$, GEE $p = 0.137$, and non-parametric Wilcoxon
125	rank sum test $p = 0.098$). The CDR, a composite of cognition and everyday function, showed a
126	significant benefit (p=0.034), and other measures showed favorable treatment effects on patterns
127	of brain glucose utilization (p=0.002) and patterning scores (p=0.0329) on 18 F-
128	fluorodeoxyglucose positron-emission tomography (FDG PET). Plasma AGE, marking
129	pharmacodynamic target engagement, were also reduced in a randomly selected subset of
130	patients (p=0.044) [6]. In this study there was a pattern of pharmacogenomic response where
131	participants without APOE ε 4 were more responsive to benfotiamine than those with APOE ε 4.
132	These preliminary results justify the testing of benfotiamine in a larger seamless phase
133	2A-phase 2B randomized controlled trial (RCT) to investigate its safety, tolerability, and efficacy
134	in early AD [18]. The BenfoTeam trial will provide the next level of necessary clinical, safety
135	and efficacy evidence to establish "Proof of Concept" (POC) for benfotiamine.

136 Materials and methods

137 **Objectives**

The primary objective of phase 2A is to determine the highest safe and well-tolerated daily dose of benfotiamine (600 mg/d or 1200 mg/d), as evaluated by the rate of tolerability events (TEs), to advance to the longer-term phase 2B study. The secondary objective of phase 2A is to evaluate additional measures of safety and tolerability of 600 mg/d or 1200 mg/d doses of benfotiamine.

The primary objective of phase 2B is to assess the efficacy of benfotiamine on global
function and cognition over 72 weeks. The secondary objectives of phase 2B are to evaluate: 1)

BenfoTeam study protocol

7

145 longer-term safety and tolerability of benfotiamine treatment, 2) the effects of benfotiamine's PK 146 relationships to primary clinical outcome measures. (plasma thiamine, and thiamine esters in whole blood, thiamine diphosphate (ThDP) and thiamine monophosphate (ThMP) and 147 erythrocyte transketolase activity), and 3) benefits of benfotiamine on everyday activities of 148 daily living and specific aspects of cognitive function (e.g., memory) over 72 weeks. 149 150 Exploratory objectives of phase 2B are to evaluate: 1) the downstream biological effects 151 of treatment with benfotiamine on measures of neurodegeneration (cortical thickness MRI, 152 plasma neurofilament light chain, total tau), neuroinflammation (plasma glial fibrillary acid 153 protein) and AD pathophysiology (plasma p-tau231, p-tau217, Aβ 42/40, p-tau217/np-tau217(ptau217 ratio) over 72 weeks, 2) the effects of benfotiamine on neuropsychiatric symptoms and 154 155 cognitive-functional composite measures, 3) the effects of benfotiamine on remotely-156 administered measures of cognition, and to compare the sensitivity of remote and in-person 157 cognitive assessments, and 4) the relationship between PK measures, including plasma thiamine, thiamine esters in whole blood (ThDP and ThMP), erythrocyte transketolase activity, and PD 158 159 measures including AGE.

160 **Design**

This overall design is a placebo controlled parallel group RCT over 72 weeks. The Phase 2A safety and dose selection decision will be reached when either 21 total TEs have been observed across both the high dose arm and the placebo arm, or when 160 person-months of exposure have accumulated in each of the high dose and placebo arms, whichever comes first (see S1 File). If the tolerability stopping rule is not reached by this predetermined number of TEs, the 1200 mg dose will continue, the 600 mg dose will be titrated upwards, and randomization will be adjusted for the remainder of trial enrollment to be 1:1 active versus

BenfoTeam study protocol

8

168	placebo across the trial population. The completion of phase 2A will seamlessly transition to
169	phase 2B without pausing or stopping the trial. Phase 2B will assess efficacy and longer-term
170	safety of benfotiamine at the selected dose in a larger group of participants through 72 weeks of
171	treatment.
172	The schedule of enrollment, interventions, and assessments is shown in Fig 1. The study
173	schematic is shown in Fig 2.
174 175	Figure 1. Schedule of enrollment, interventions, and assessments
176	Figure 2. Study schematic
177	
178	Participants
179	This trial (NCT06223360) will include 406 participants with early AD, including
180	participants with MCI or mild dementia due to AD according to NIA-AA Diagnostic Criteria
181	with a positive plasma AD biomarker test result (C ₂ N PrecivityAD2; APS2 value >47.5) [19-22].
182	Key inclusion criteria include aged 50-89, Mini-Mental State Examination (MMSE) total score
183	20-30, Montreal Cognitive Assessment (MoCA) <26, and CDR score of 0.5 or 1 with memory
184	score of ≥ 0.5 at screening. A complete list of inclusion criteria is presented in Table 1. Key
185	exclusion criteria include any significant neurological or neurodegenerative disorder (other than
186	AD), uncontrolled depression or major depression, a current diagnosis of uncontrolled type I or
187	type II diabetes mellitus, a diagnosis of cancer (unless no evidence of recurrence for 5 years),
188	any other major psychiatric disorder or active medical condition that impairs cognition or
189	impacts participation, MRI at screening shows evidence of infection, tumor, cortical infarction,
190	or multiple lacunes in prefrontal or critical memory regions, and initiation of a monoclonal
191	antibody treatment targeting brain amyloid (including lecanemab, aducanumab, solanezumab,

BenfoTeam study protocol

9

- donanemab) within 6 months. A list of exclusion criteria is presented in Table 2. Recruitment
- and enrollment of participants will occur through the Alzheimer's Disease Cooperative Study
- 194 (ADCS) network at approximately 50 sites in the United States. A list of participating sites can
- 195 be viewed at <u>www.clinicaltrials.gov</u>.

196 **Table 1. Inclusion criteria**

	Inclusion criteria
1.	Aged 50 to 89 (inclusive) at screening.
2.	Mild Cognitive Impairment due to AD or Mild probable AD (NIA-AA ^{1,2}).
3.	Mini-Mental State Examination (MMSE) score 20-30 inclusive at screening.
4.	Montreal Cognitive Assessment score (MoCA) < 26 at screening.
5.	Clinical Dementia Rating (CDR) global score of 0.5 or 1 with memory score of ≥ 0.5 at
-	screening.
6.	Positive plasma AD biomarker signature:
	a. Plasma test (C_2N PrecivityAD2). To qualify participants will have a High
	Amyloid Probability Score (APS2 >47.5).
	b. If previously treated with any anti-amyloid monoclonal antibody (AAMA) and
	C2N PrecivityAD2 is negative, documentation of a pre-AAMA treatment positive
7	amyloid status with either amyloid PET, CSF, or appropriate plasma test.
7.	Stable dosage of AchEIs and/or memantine for at least 3 months prior to screening.
8.	Availability of a study partner who has frequent interaction with the participant
-	(approximately >3-4 times per week) and is available for all study visits.
9.	For FDA-approved monoclonal antibodies targeting brain amyloid (including lecanemab,
	aducanumab, solanezumab, donanemab), participants must be on stable dose of treatment
10	for at least 6 months prior to screening.
10.	Women must be post-menopausal for at least one year or surgically sterile
	(bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months
	prior to screening.
11.	Fluent in English or Spanish.
12.	Living in the community (includes assisted living facilities).
13.	Ambulatory, or able to walk with an assistive device.
14.	Informed consent from the participant (or the participant's legally authorized
	representative if lacking decisional capacity), as well as study partner consent.

¹⁹⁷

204

¹⁹⁸ Note. ¹ Albert, M.S., et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease:

¹⁹⁹ recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic

²⁰⁰ guidelines for Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 270-9.² McKhann, G.M., et al., The

²⁰¹ diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-

²⁰² Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia,

^{203 2011. 7(3):} p. 263-269.

205 Table 2. Exclusion criteria

Exclusion Criteria		
1.	Significant neurological disorder other than AD including hypoxia, stroke, traumatic brain injury.	
2.	Diagnosis of uncontrolled depression or major depression, as determined by DSM-IV, unless successfully treated.	
3.	Any other major psychiatric disorder that impairs cognition or impacts participation in the study is exclusionary. Participants with major psychiatric disorders (e.g., severe generalized anxiety disorder, bipolar disorder, schizophrenia etc.) where the condition is felt to be the most significant contributor to the cognitive impairment should be excluded.	
4.	Active medical conditions that impair cognition or impact participation in the study, other than AD should be exclusionary. Participants with medical conditions (e.g., severe obstructive sleep apnea) in whom the condition is felt to be the most significant contributor to the cognitive impairment should be excluded.	
5.	Significant neurodegenerative diseases, other than AD, and other causes of dementias.	
6.	A current diagnosis of uncontrolled type I or type II diabetes mellitus, as defined by Hemoglobin A1 C (Hb A1C $>$ 8).	
7.	A current active, uncontrolled seizure disorder.	
8.	 Participation in another clinical trial for an investigational agent of: a. Symptomatic medications, participation is excluded within 4 weeks prior to the screening visit. b. Disease-modifying medications, participation is excluded within 6 months of the screening visit. 	
9.	Previous exposure to benfotiamine within past 3 months.	
10.	Current serious or unstable medical illness that could interfere with the interpretation of safety and assessment of efficacy in this study.	
11.	Diagnosis or treatment of cancer within the past 5 years.	
12.	History of alcoholism or substance abuse, current or within past 5 years.	
13.	Contraindication to MRI.	
14.	MRI at screening showing evidence of infection, tumor, cortical infarction, or multiple lacunes in prefrontal or critical memory regions.	
15.	Initiation of an FDA-approved monoclonal antibody treatment targeting brain amyloid (including lecanemab, aducanumab, solanezumab, donanemab) within 6 months prior to the screening visit.	
16.	A disability that may prevent the patient from completing all study requirements in the opinion of the PI.	

206

207 **Concomitant medications**

208 Use of the following medications is prohibited throughout participation in the study:

thiamine or benfotiamine supplements outside of a multivitamin, immunosuppressive

10

11

medications, chemotherapeutic agents for malignancy, or any concomitant treatment which may
impair cognitive function. Medications that are central nervous system active (e.g., hypnotics)
and may affect cognitive function are not permitted for 72 hours prior to neuropsychological
testing.

Eligible participants being treated with FDA-approved acetylcholinesterase inhibitors 214 (AchEI) and/or memantine at the time of screening are expected to remain on a stable dosage 215 216 regimen of these medications for the duration of the trial. They may be initiated as clinically 217 indicated during the study when a participant is not already on these medications at the outset, 218 with appropriate documentation. FDA-approved monoclonal antibodies targeting brain amyloid 219 are permitted, but participants must be stable for at least 6 months on such treatment prior to 220 screening. For medications not intended to treat AD, participants must be on a stable dose for at 221 least 4 weeks prior to baseline, except for medications which are administered for a short course 222 of treatment.

223 Interventions

Benfotiamine capsules, 300 mg, 600 mg, or placebo are provided as opaque dark green (chlorophyll) colored capsules for oral administration. The placebo group will receive capsules with microcrystalline cellulose, with all other components, shape, and color identical to the active treatment. Participants are assigned capsules twice a day (BID; once in the morning and once in the evening). Participants receive a new supply for each dosing period between study visits and are provided a diary to track daily intake and timing of dose. During study visits, participant drug supply will be assessed for compliance.

231 Randomization and blinding

BenfoTeam study protocol

12

232	A randomization schedule will be generated and incorporated into an electronic
233	Randomization and Trial Supplies Management (RTSM) system. The treatment group will be
234	assigned as the site randomizes the participant. In phase 2A of the trial, as shown in Figure 2,
235	each participant will be randomly allocated in a 1:1:1 ratio into one of the 3 groups: 1200 mg/day
236	benfotiamine, 600 mg/day benfotiamine or placebo. At the dose decision point that ends phase
237	2A, all participants enrolled in the two phase 2A active dose arms will receive a new supply of
238	benfotiamine at the selected highest tolerable dose for phase 2B. An unscheduled visit at the start
239	of phase 2B may be required to replace investigational product (IP) supply in all active
240	participants once the phase 2A dose selection is made. Newly enrolled participants will be
241	randomized 1:2 active arm to placebo arm until parity is achieved between numbers of active and
242	placebo arm participants (approximately 150 participants total), randomized 1:1 thereafter
243	(approximately 100 participants). In both phases of the trial, the randomization will be stratified
244	by site.

Participants and study personnel will be blinded to both treatment arm and dosage. There
will be provisions for the site Principal Investigator (PI) to unblind treatment assignment in
consultation with the ADCS Medical Monitor only in the case of an emergency.

248 Adverse events

All AEs (i.e., a new event or an exacerbation of a pre-existing condition in its frequency or severity) that occur from the time of consent and up to 30 days after the IP has been discontinued will be recorded. A treatment emergent AE (TEAE) is defined as any AE that developed, worsened, or became serious after first dose of IP and prior to 30 days after the last dose of IP. A serious adverse event (SAE) is an AE that results in any of the following outcomes: death, life-threatening situation (participant is at immediate risk of death), inpatient

BenfoTeam study protocol

PLOS ONE v1.0 17APR2024

255	hospitalization or prolongation of existing hospitalization, persistent or significant
256	disability/incapacity, congenital anomaly/birth defect in the offspring of a patient who received
257	IP, or considered significant by the investigator for any other reason. All AEs will be followed
258	until resolution or until the Investigator and/or the Medical Monitor determine the event is
259	chronic or clinically stable.
260	Safety Surveillance
261	During both phases of the trial, safety surveillance includes monitoring of 1)
262	AEs/TEAEs/SAEs summarized by grade, attribution, and body systems, by number of events,
263	and by participant, 2) physical exam abnormalities, 3) vital signs (weight, blood pressure, pulse
264	rate, temperature, respiration rate), 4) standard 12-lead resting ECG measures, and 4) summaries
265	of safety laboratory tests.
266	Outcomes
267	Phase 2A primary endpoints
268	The primary safety endpoint in phase 2A is the rate of TEs in active and placebo arms at
269	each dose. A TE is defined as early discontinuation of the IP due to intolerability or a post-
270	randomization moderate or severe AE that is possibly, probably or definitely related to the IP.
271	Phase 2A secondary endpoints
272	Secondary safety and tolerability endpoints for phase 2A include: 1) number of
273	participants with AEs/TEAEs and SAEs, 2) number of participant withdrawals from the study,
274	and 3) number of participants discontinuing IP.
275	Phase 2B primary endpoints

BenfoTeam study protocol

14

276	The primary cognitive endpoint is the within-participant change from baseline to 72
277	weeks compared between active arm and placebo on the ADAS-Cog13 [23, 24]. The primary
278	functional endpoint is the within-participant change from baseline to 72 weeks compared
279	between active arm and placebo on the CDR-Sum of Boxes (SB) [25, 26].

280 Phase 2B secondary safety and tolerability endpoints

281 Secondary safety and tolerability endpoints for phase 2B include: 1) number of

282 participants with AEs/TEAEs and SAEs 2) number of participant withdrawals from the study,

and 3) number of participants discontinuing IP.

284	Phase 2B	secondary	PK	endpoints
-----	----------	-----------	----	-----------

Secondary PK endpoints for phase 2B include mean and median levels of: 1) thiamine
(nmol/L), 2) thiamine diphosphate (ThDP) (nmol/L), 3) thiamine monophosphate (ThMP)
(nmol/L) [27], and 4) erythrocyte transketolase activity (U/g haemoglobin (U/gHb)) [28, 29].
Measures of ThDP, ThMP, and erythrocyte transketolase activity will be provided as blood
markers of efficacy of drug delivery. These measurements will be conducted on whole and red
blood cells in samples collected at baseline, week 8, and week 72.

291 Phase 2B secondary efficacy endpoints

Additional efficacy endpoints of benfotiamine will be assessed by within-participant change from baseline to week 72 between active arm and placebo on the following: 1) the Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-ADL-MCI) [30] to evaluate preservation or potential improvement in everyday activities of daily living, and 2) the MoCA [31] to evaluate preservation or potential improvement in cognitive function.

BenfoTeam study protocol

15

298 Phase 2B exploratory endpoints

299	Exploratory endpoints in phase 2B include within-participant longitudinal change
300	between active arm and placebo in: 1) cranial MRI volumetric measures of hippocampal, whole
301	brain, and ventricles, as well as regional cortical thickness, 2) scores on the Neuropsychiatric
302	Inventory (NPI) [32], 3) scores on neuropsychological test measures administered remotely and
303	in-person, 4) ADAS-Cog-Exec [33] scores, 5) levels of plasma biomarkers Aβ42/Aβ40 ratio, p-
304	tau217/np-tau217 ratio, p-tau217, total tau, p-tau 231, NfL and GFAP, 6) AGE levels measured
305	in plasma as an exploratory endpoint of PD, and 7) PK (plasma thiamine, thiamine esters in
306	whole blood including ThDP and ThMP, and erythrocyte transketolase activity) relationships to
307	PD biomarkers (AGE) and clinical outcome measures.
308	AGE levels will be measured on plasma samples and four AGE by mass spectrometry
309	(N(6)-carboxymethyl-lysine (CML), pentosidine, N(6)-carboxymethyl-lysine (CEL),
310	methylglyoxal-derived hydroimidazolone) will be quantified to measure all specific modes of
311	action of benfotiamine.
312	Neuropsychological measures administered in-person include the Boston Naming Test
313	(30-item) [34], the Trail Making Test (Parts A and B) [35], and WAIS-R Digit Symbol
314	Substitution [36]. Neuropsychological measures administered remotely (via video-call) include
315	Immediate and Delayed Recall from the Rey Auditory Verbal Learning Test [37], Number Span
316	Forward and Backward [38], Category Fluency [39] and Letter Fluency [39]. Remote measures
317	will be administered over videoconference-call within 10 days after each in-person visit
318	(baseline, week 24, week 48, and week 72). Participants will use their own interactive video
319	capable devices for the remote assessments, although study-provided devices will be available,
320	as needed.

BenfoTeam study protocol

16

Power calculation and sample size

322	Table 3 shows that with a total sample size of n=406 (203/arm), a 20% dropout rate, and
323	a 5% drop-in rate from the placebo arm to active treatment, the trial will be powered at 80%
324	overall (90% on each endpoint separately) to detect a difference between arms, corresponding to
325	a Cohen's d effect size of 0.38 which represents a small to moderate effect size. This would be a
326	reasonable and clinically relevant difference between arms on each co-primary endpoint, and
327	would be commensurate to the 35% to 40% amelioration of decline seen in the placebo arm of
328	the recently completed phase 2 trial of donanemab in patients with early AD [40], and would
329	correspond to an absolute difference between arms on the CDR-SB of 0.7 points (assumed $SD =$
330	1.74) and of 1.7 points (assumed $SD = 4.35$) on the ADAS-Cog13.
331	

Table 3. Sample sizes which achieve 90% power for given effect sizes (Cohen's D;

difference between the 2 arms), assuming 20% dropout and assuming drop-in rates of 5%

and 10%

drop-in rate	effect size	n / arm
5%	0.35	239
5%	0.38	203
5%	0.40	183
10%	0.35	266
10%	0.38	226
10%	0.40	204

335

336 Statistical analyses

337 Phase 2A

338 When criteria have been reached to end phase 2A, the unblinded safety biostatistician

339 will alert the PIs (HHF, JAL, GEG) that the database is to be frozen. An unblinded safety report

17

340 will be provided to the Data Safety Monitoring Board (DSMB). The phase 2A primary analysis 341 will compare the rate of TEs between the 1200 mg/day arm and the placebo arm. The analysis will test whether the rate of TEs is unacceptably high in this high-dose arm compared to placebo, 342 343 using a formal one-sided hypothesis test of equal rates, against the one-sided alternative that the high dose arm TE rate is greater than the placebo arm TE rate. The conditional one-sided test of 344 345 Przyborowski and Wilenski [41] will be used, at 5% significance level. Additional phase 2A safety analyses will involve computing an exact upper-one sided 346 95% confidence interval for the TE rate in each arm. Safety and tolerability data and 347

demographic data will be summarized in a tabular and/or graphical format for each treatment

349 group. The incidence of all laboratory test abnormalities and median changes from baseline will

be tabulated by treatment regimen and time point. The safety population (i.e., enrolled and

randomized participants who received at least 1 dose of blinded study therapy) will be used forthese analyses.

___ __

353 Phase 2B

The primary analyses will be performed on the modified intent to treat (mITT) population 354 355 which includes all randomized participants who took at least one dose of the study medication, 356 have a baseline assessment of the co-primary efficacy endpoints, and have at least one efficacy 357 evaluation following baseline. The primary analysis will be the same for each co-primary 358 endpoint (CDR-SB and ADAS-Cog13) and will test within subject change in the measure as the 359 outcome in a mixed effects repeated measures model using all available outcomes in the mITT population with no imputation for missing data. Fixed effects in the model will be APOE status, 360 361 baseline value of the outcome measure, baseline by visit-week interaction term, treatment group, 362 visit-week, and visit-week by treatment group interaction. The approach will be maximum

BenfoTeam study protocol

18

363 likelihood. Visit will be treated as a categorical variable. The covariance structure will be 364 specified as follows: the random effects will include site and subject. The within-subject covariance will be unstructured. If needed, sites will be pooled (in order of enrollment, starting 365 366 from minimum enrollment) so that there is a minimum of 5 participants per site. If the model fails to converge at the default setting for the software used, then site will be changed to a fixed 367 368 effect, and if this model does not converge, site will be removed from the model. If the model 369 does not converge, the following structures for the within subject covariance will be fit, 370 sequentially, until the structure is found that results in convergence of the model: Huynh-Feldt, 371 Toeplitz, Autoregressive (1), and Compound Symmetry. A sandwich estimator will be utilized to estimate the variance estimates, and degrees of freedom will be calculated using the between-372 within method. The primary endpoint will be tested using model-adjusted least squares means at 373 374 the week 72 visit. Point estimates, standard errors, two-sided 95% confidence intervals, and p-375 values will be presented.

Mean changes in the secondary endpoints from baseline to week 72 will be compared 376 between arms using the analysis strategy outlined above. To control alpha over the primary and 377 378 all secondary endpoints, an overall hierarchical gatekeeper strategy will be used, similar to the 379 primary analysis. First, if the primary analysis is not significant, then the secondary endpoints 380 will not be formally tested, and will be presented using exploratory summary statistics only (means and uncorrected 95% confidence intervals by arm and for the difference between arms). 381 382 No claims of statistical significance will be made. However, if the primary analysis is significant, the secondary endpoints will be tested in the listed order in hierarchical manner, each using an 383 alpha of 5%. Once a secondary endpoint has failed to attain the prespecified 5% significance 384 385 level, the remaining secondary endpoints will be presented as exploratory only. This strategy will

BenfoTeam study protocol

19

386 maintain the overall familywise significance level for the primary and all secondary endpoints at 387 5%. Exploratory analyses will be detailed in the statistical analysis plan, and will generally be similar to the primary and secondary analyses. 388

Safety and tolerability data as well as demographic data for the safety population will be 389 summarized in tabular and/or graphical format for each treatment group. The incidence of all 390 391 laboratory test abnormalities and the median changes from baseline will be tabulated by 392 treatment regimen and time point.

393

Data safety monitoring board

394 The DSMB will provide safety oversight of the trial. It is independent from the ADCS 395 and reports to the National Institute on Aging (NIA) through its project scientist. The DSMB 396 includes a chair and 4 other experts in the field who have the appropriate background for these 397 responsibilities and have been approved by the NIA. Other members may be added depending on 398 the needs of the trial. The DSMB will meet quarterly and on an ad-hoc basis in the face of any 399 important safety matters that may arise, and will provide recommendations following each meeting. The final recommendation on dose to select at the end of phase 2A for use in phase 2B 400 401 will be made by the DSMB. The DSMB will have the authority to recommend that the study be 402 halted or discontinued.

Early discontinuation 403

The entire study may be otherwise discontinued at the discretion of the ADCS or the 404 study PIs (GEG, JAL, HHF) for administrative or other reasons. Participants are free to withdraw 405 406 from study participation at any time, for any reason, and without prejudice. Discontinuation of study treatment and/or the participation of an individual patient can occur in the following 407 408 circumstances: 1) withdrawal of informed consent by the participant or legally authorized

BenfoTeam study protocol

20

409	representative (LAR), 2) treatment with a non-permitted concomitant medication, 3) AE or other
410	significant medical condition which, in the opinion of the Investigator, render it necessary to
411	discontinue study drug, 4) medical emergency that necessitates unblinding the participant's
412	treatment assignment, 5) any other occurrence that, in the PIs opinion, makes continued
413	participation contrary to the participant's best interest, or 6) movement of the participant into a
414	long-term care nursing facility. Participants who discontinue study treatment for any reason will
415	have the opportunity to continue on the protocol to the end of the study with their ongoing
416	consent.

417

7 Monitoring & quality control

During the study each site will be monitored at regular intervals by an ADCS clinical 418 419 research monitor through a combination of on-site visits and remote monitoring procedures. The 420 monitoring visits will be conducted according to the applicable International Conference on 421 Harmonization (ICH) and Good Clinical Practice (GCP) guidelines to ensure protocol adherence, 422 quality of data, drug accountability, compliance with regulatory requirements, and continued adequacy of the investigation site and its facilities. Documentation of all quality control 423 424 procedures will be outlined in the Data Management Plan. Edit checks and listings will be run 425 and used in conjunction with electronic case report form pages to support clinical review of the data. 426

427 Ethics

Review and approval of the protocol and the associated informed consent documents and
recruitment materials was conducted by the central Institutional Review Board (IRB) Advarra.
Approval from the central IRB will be obtained for all protocol amendments and changes to the

21

431	informed consent document when they are warranted. The site investigator will notify the central
432	IRB of deviations from the protocol or SAEs occurring at the site.
433	No study-specific procedure will be undertaken on any individual patient until that
434	patient or their LAR has given written informed consent to take part in the study. The study
435	partner must also participate in the consenting process. Participant confidentiality is strictly held
436	in trust by the participating investigators, research staff, and the sponsoring institution and their
437	agents.

438 **Trial Status**

Recruitment for this study began March 22, 2024 and is currently ongoing.

440 **Dissemination plan**

441 Study results will be published in accordance with the 2010 Consolidated Standards of 442 Reporting Trials (CONSORT) guidelines. As there are expected to be too few participants at 443 each site for an individual site's results to be statistically valid, the results of this study will be 444 disclosed or published only in combined form based upon the statistical analysis coordinated and 445 performed by the ADCS. Results will be posted on clinicaltrials.gov in accordance with 446 requirements.

447 **Discussion**

There is an urgent need to accelerate and diversify therapeutic possibilities for patients with AD [8]. Benfotiamine provides an important novel therapeutic direction in AD as it addresses and treats a well-characterized tissue thiamine action deficiency and related changes in glucose metabolism as well as post-translational modifications including those promoting plaque [2] and tangle formation [3], neuroinflammation [4, 5], neurodegeneration [6], and AGE [7]. Benfotiamine has potential to achieve POC, with the possibility of additive or synergistic effects

22

to other current therapeutic approaches, addressing the US National Alzheimer's Project Act
(NAPA) goal of combining targets [8]. The preliminary results of a pilot study provide proof of
principle that justify testing the efficacy of benfotiamine in a larger RCT to investigate its safety,
tolerability, and efficacy in early AD [6, 18].

The BenfoTeam trial is deploying an innovative seamless phase 2A-2B design to achieve 458 POC. This is a double-blind, placebo-controlled RCT of 72-weeks of benfotiamine in early AD 459 460 with a randomized sample of 406 participants. It includes an adaptive dose decision rule that 461 optimizes exposure to the highest and best-tolerated dose. An additional innovation is the use of 462 plasma-based amyloid and p-tau biomarker tests for inclusion, which provides an important contribution by shifting away from invasive testing using lumbar puncture or expensive PET 463 464 scanning that entails significant radiation exposure. This phase 2A-2B trial is powered to provide 465 evidence of clinically important benefit and, if positive, it will further validate our approach of 466 deploying seamless designs with adaptive dose finding, and will provide measures and effect 467 sizes that can become new benchmarks.

Results from the BenfoTeam trial are expected to identify the highest well-tolerated dose of benfotiamine that has an acceptable safety profile. Measurable PK and PD biomarkers and a constellation of downstream plasma AD and neurodegenerative biomarkers ensure that the trial will be able to test the sufficiency of target engagement and dose while evaluating longer term efficacy and safety. In addition, the sample size is well powered to determine if benfotiamine will benefit cognition and everyday function in individuals with early AD.

474 Authors Contributions

475 **Conceptualization:** Howard H. Feldman, Gary E. Gibson, José A. Luchsinger.

23

476 **Project Directors/Principal Investigators:** Howard H. Feldman, Gary E. Gibson, José A.

- 477 Luchsinger.
- 478 Funding Acquisition: Howard H. Feldman, Gary E. Gibson [contact principal investigator],
- 479 José A. Luchsinger.
- 480 Methodology: Howard H. Feldman, Gary E. Gibson, José A. Luchsinger, Karen Messer, Steven
- 481 D. Edland, Diane M. Jacobs, David P. Salmon, Sarah A. Flowers, Kerry S. Jones, Albert
- 482 Koulman, Philip B. Verghese, Venky Venkatesh, Kevin Yarasheski, Henrik Zetterberg.
- 483 **Project Administration:** Carolyn Revta.
- 484 Writing Original Draft Preparation: Howard H. Feldman, January Durant, Jody-Lynn Lupo.
- 485 Writing Review & Editing: Howard H. Feldman, Gary E. Gibson, José A. Luchsinger,
- 486 Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Karen Messer, Steven D.
- 487 Edland, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Philip B. Verghese,
- 488 Venky Venkatesh, Kevin Yarasheski, Henrik Zetterberg, January Durant, Jody-Lynn Lupo.

489 Acknowledgments

490

492

- 491 The members of the ADCS BenfoTeam Study Group are as follows:
- 493 ADCS: Department of Neurosciences, Alzheimer's Disease Cooperative Study, University of
- 494 California, San Diego, CA, USA.
- 495 ADCS Co-Directors: Howard H. Feldman, Judy Pa.
- 496 **Project Directors:** Gary E. Gibson (contact PI), José A. Luchsinger, Howard H. Feldman.
- 497 **Executive Operations:** Carolyn Revta.

24

- 498 Clinical Operations: Savannah Aries, Briana Askew*, Kemi Badru*, Veronica Fernandez,
- 499 Nisha Johal*, Tamesha Lucas, Bryce Truver, Erika Velazco.
- 500 Clinical Monitoring: R. Michelle Brill, Laura Cole, Edward Fox, Ben Germain, Don Guterwill,
- 501 Bailey Hoffman, Tiffany Jones, Janet Kastelan, Ike Monye*, Susan Mroz, Gerald Rivera*,
- 502 Rebecca Ryan-Jones*, Vicky Syed*, Kheshini De Zoysa.
- 503 **Regulatory/Quality Management:** Pat Chinwattana, Lori Houghtaling, Roxana Phillips, Teresa
- 504 Ruiz, Rick Seghers.
- 505 Data Management: Susan Castellino*, Sneha Jasti, Jim Krooskos, Andrew MacKelfresh,
- 506 Keerthi Vemuri, Zel Zorin.
- 507 Medical Safety: Gabriel Leger, Alessandra Pol, Curtis Taylor.
- 508 Instruments: Diane M. Jacobs, David P. Salmon.
- 509 **Recruitment:** Daniel Bennett, Andrea LaCroix, Genevieve Matthews, Donna Tan.
- 510 **Imaging:** James Brewer, Nichol Ferng, Robin Jennings.
- 511 **Statistics:** Steven D. Edland, Shelia Jin, Karen Messer, Jing Zhang.
- 512 **Special Projects/Medical Writing:** January Durant, Jody-Lynn Lupo.
- 513 **Biomarker/Lab Studies:** Sarah A. Flowers, University of Virginia, Charlottesville, Virginia,
- 514 United States of America; Kerry S. Jones, Damon A. Parkington, Sarah R. Meadows and Albert
- 515 Koulman, University of Cambridge, Cambridge, United Kingdom; Kevin Yarasheski, Philip B.
- 516 Verghese, and Venky Venkatesh, C₂N Diagnostics, St. Louis, Missouri, United States of America;
- 517 Henrik Zetterberg, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- 518 *no longer active at ADCS or with this project

BenfoTeam study protocol

25

519 **Supporting Information**

- 520 S1 File. Statistical Methods: Transition from Phase 2A to Phase 2B
- 521 S2 File. Data sharing statement
- 522 S3 File. The protocol approved by the ethics committee
- 523 S4 File. Model consent form
- 524 S1 Checklist. SPIRIT 2013 checklist

525 **References**

- Alzheimer's Association, et al., 2017 Alzheimer's disease facts and figures. 2017,
 Alzheimer's Dementia, 2017. 13(4): p. 325-373.
- Yang, Y., et al., *Succingulation Links Metabolic Reductions to Amyloid and Tau Pathology*. 2019, bioRxiv.
- 530 3. Tapias, V., et al., *Benfotiamine treatment activates the Nrf2/ARE pathway and is*
- 531 *neuroprotective in a transgenic mouse model of tauopathy.* Hum Mol Genet, 2018.
- 532 **27**(16): p. 2874-2892.
- 4. Anandam, K.Y., et al., *Proinflammatory cytokines inhibit thiamin uptake by human and*
- 534 mouse pancreatic acinar cells: involvement of transcriptional mechanism(s). Am J
- 535 Physiol Gastrointest Liver Physiol, 2021. **320**(1): p. G108-G116.
- 536 5. He, Y., et al., *Glyoxalase system: A systematic review of its biological activity, related-*
- *diseases, screening methods and small molecule regulators.* Biomed Pharmacother, 2020.

131: p. 110663.

539	6.	Gibson, G.E., et al., Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results
540		of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J Alzheimers Dis, 2020.
541		78 (3): p. 989-1010.
542	7.	Chou, P.S., et al., Effect of Advanced Glycation End Products on the Progression of
543		Alzheimer's Disease. J Alzheimers Dis, 2019. 72(1): p. 191-197.
544	8.	Alkhalaf, A., et al., Effect of benfotiamine on advanced glycation endproducts and
545		markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One,
546		2012. 7 (7): p. e40427.
547	9.	Depeint, F., et al., Marginal thiamine deficiency increases oxidative markers in the
548		plasma and selected tissues in F344 rats. Nutrition Research, 2007. 27(11): p. 698-704.
549	10.	Victor, M., R.D. Adams, and G.H. Collins, The Wernicke-Korsakoff syndrome. A clinical
550		and pathological study of 245 patients, 82 with post-mortem examinations. Contemp
551		Neurol Ser, 1971. 7: p. 1-206.
552	11.	Gibson, G.E., et al., Reduced activities of thiamine-dependent enzymes in the brains and
553		peripheral tissues of patients with Alzheimer's disease. Arch Neurol, 1988. 45(8): p. 836-
554		40.
555	12.	Gibson, G.E., et al., Alpha-ketoglutarate dehydrogenase complex-dependent
556		succinylation of proteins in neurons and neuronal cell lines. J Neurochem, 2015. 134(1):
557		p. 86-96.
558	13.	Bubber, P., et al., Mitochondrial abnormalities in Alzheimer brain: mechanistic
559		implications. Ann Neurol, 2005. 57(5): p. 695-703.
560	14.	Gibson, G.E., et al., Vitamin B1 (thiamine) and dementia. Ann N Y Acad Sci, 2016.
561		1367 (1): p. 21-30.

BenfoTeam study protocol

27

562	15.	Ramamoorthy, K., et al., Alzheimer's disease is associated with disruption in thiamin
563		transport physiology: A potential role for neuroinflammation. Neurobiol Dis, 2022. 171:
564		p. 105799.
565	16.	Suzuki, K., et al., High-dose thiamine prevents brain lesions and prolongs survival of
566		Slc19a3-deficient mice. PLOS ONE, 2017. 12(6): p. e0180279.
567	17.	Pan, X., et al., Powerful beneficial effects of benfotiamine on cognitive impairment and
568		beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.
569		Brain, 2010. 133(Pt 5): p. 1342-51.
570	18.	Gibson, G.E., et al., Pharmacological thiamine levels as a therapeutic approach in
571		Alzheimer's disease. Front Med (Lausanne), 2022. 9: p. 1033272.
572	19.	Albert, M.S., et al., The diagnosis of mild cognitive impairment due to Alzheimer's
573		disease: recommendations from the National Institute on Aging-Alzheimer's Association
574		workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011.
575		7 (3): p. 270-9.
576	20.	McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer's disease:
577		Recommendations from the National Institute on Aging-Alzheimer's Association
578		workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia,
579		2011. 7 (3): p. 263-269.
580	21.	Rissman, R.A., et al., <i>Plasma Aβ42/Aβ40 and phospho</i> \Box <i>tau217 concentration ratios</i>
581		increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
582		Alzheimer's & Dementia, 2023.
583	22.	Meyer MR, K.K., Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V,

584 Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C,

585		Bateman RJ, Holtzman DM, Irizarry M, Verbel D, Sachdev P, Ito S, Contois J,
586		Yarasheski KE, Braunstein JB, Verghese PB, West T., Clinical Validation of the
587		$PrecivityAD2^{TM}$ blood test: A mass spectrometry-based test with algorithm combining
588		%p-tau217 and A β 42/40 ratio to identify presence of brain amyloid. Alzheimer's
589		Dement, 2024. in press.
590	23.	Rosen, W.G., R.C. Mohs, and K.L. Davis, A new rating scale for Alzheimer's disease.
591		Am J Psychiatry, 1984. 141(11): p. 1356-64.
592	24.	Mohs, R.C., et al., Development of cognitive instruments for use in clinical trials of
593		antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden
594		its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord,
595		1997. 11 Suppl 2 : p. S13-21.
596	25.	O'Bryant, S.E., et al., Validation of the new interpretive guidelines for the clinical
597		dementia rating scale sum of boxes score in the national Alzheimer's coordinating center
598		database. Arch Neurol, 2010. 67(6): p. 746-9.
599	26.	O'Bryant, S.E., et al., Staging dementia using Clinical Dementia Rating Scale Sum of
600		Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol, 2008. 65(8):
601		p. 1091-5.
602	27.	Gallant, J., et al., Low-dose thiamine supplementation of lactating Cambodian mothers
603		improves human milk thiamine concentrations: a randomized controlled trial. Am J Clin
604		Nutr, 2021.
605	28.	Jones, K.S., et al., Erythrocyte transketolase activity coefficient (ETKAC) assay protocol
606		for the assessment of thiamine status. Annals of the New York Academy of Sciences,
607		2021. 1498 (1): p. 77-84.

BenfoTeam study protocol

608	29	Jones, K.S., et al.	Protocol and	application o	f basal erythroc	vte transketolase	activity to
000	<i>L</i>).	JUICS, IX.S., Ct al.	, 1 1010001 4114	upplication of] Dasai er yinnoc	yie manskeioluse	

- 609 *improve assessment of thiamine status*. Annals of the New York Academy of Sciences,
- 610 2023. **1521**(1): p. 104-111.
- 611 30. Galasko, D., et al., *An inventory to assess activities of daily living for clinical trials in*
- 612 *Alzheimer's disease. The Alzheimer's Disease Cooperative Study.* Alzheimer Dis Assoc
- 613 Disord, 1997. **11 Suppl 2**: p. S33-9.
- 614 31. Nasreddine, Z.S., et al., *The Montreal Cognitive Assessment, MoCA: a brief screening*
- 615 *tool for mild cognitive impairment*. J Am Geriatr Soc, 2005. **53**(4): p. 695-9.
- 616 32. Cummings, J.L., *The Neuropsychiatric Inventory: assessing psychopathology in dementia*
- 617 *patients*. Neurology, 1997. **48**(5 Suppl 6): p. S10-16.
- 33. Jacobs, D.M., et al., *Development of a novel cognitive composite outcome to assess*
- 619 *therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS-Cog-*
- 620 *Exec.* Alzheimers Dement (N Y), 2020. **6**(1): p. e12059.
- 34. Kaplan, E., H. Goodglass, and S. Weintraub, *The Boston Naming Test*. Philadelphia: Lea
 and Febiger, 1983.
- 623 35. Office, A.G.s., Manual of Directions and Scoring. In: Army Individual Test Battery.
- Washington DC: War Department, 1944.
- 36. Wechsler, D., *Wechsler Adult Intelligence Scale-Revised.*; 1981. The Psychological
 Corporation, 1981.
- 827 37. Rey, A., *L'examen Clinique en psychologie*. Paris: Presses Universitaires de France,
 828 1964.
- 38. Besser, L., et al., *Version 3 of the National Alzheimer's Coordinating Center's Uniform*
- 630Data Set. Alzheimer Dis Assoc Disord, 2018.

631	39.	Morris, J.C., et al., The Consortium to Establish a Registry for Alzheimer's Disease
-----	-----	--

- 632 *(CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.*
- 633 Neurology, 1989. **39**(9): p. 1159-65.
- 40. Mintun, M.A., et al., *Donanemab in Early Alzheimer's Disease*. N Engl J Med, 2021.
- 635 **384**(18): p. 1691-1704.
- 41. Przyborowski, J. and H. Wilenski, *Homogeneity of results in testing samples from*
- 637 *Poisson series: With an application to testing clover seed for dodder.* Biometrika, 1940.
- 638 **31**(3-4): p. 313-323.

639

640

			STUDY PERIOD									
	Enrollment	Allocation		Post-allocation							End	
Visit Number	1	2	3	4	5	6	7	8	9	10	11	
TIMEPOINT	Screening	Baseline	Wk 4	Wk 8	Wk 12	Wk 24	Wk 36	Wk 48	Wk 60	Wk 72	Wk 76	
ENROLLMENT:												
Informed consent	Х											
Eligibility review	Х	Х										
Allocation		Х										
INTERVENTIONS:												
Benfotiamine1200mg/day*		+										
Benfotiamine 600mg/day*		+										
Placebo		+										
* Phase 2A of the trial will randomiand well-tolerated dose of benfotian	ze participants 1:1:1 nine (1200mg/day o	to 1200 mg/day b r 600mg/day) will	benfotiamir be carried	ne, 600 mg forward to	/day benfot phase 2B.	iamine or p	lacebo. At tl	he end of pl	nase 2A, on	ly the highe	st safe	
ASSESSMENTS:												
CDR	Х					Х		Х		Х		
ADAS-Cog13		Х				Х		Х		Х		
ADCS-ADL-MCI		Х				Х		Х		Х		

Figure 1. Schedule of enrollment, interventions, and assessments

			STUDY PERIOD									
	Enrollment	Allocation		Post-allocation							End	
Visit Number	1	2	3	4	5	6	7	8	9	10	11	
TIMEPOINT	Screening	Baseline	Wk 4	Wk 8	Wk 12	Wk 24	Wk 36	Wk 48	Wk 60	Wk 72	Wk 76	
MoCA	Х					Х		Х		Х		
Concomitant Medication	+											
Adverse Events		+										
12-lead ECG (resting)	Х					Х				Х		
Safety Blood Tests	+											
TSH, Hemoglobin Alc, Infectious Disease Serology, Urinalysis	Х											
Blood Sampling for PD: AGE		х		Х						Х		
Blood Sampling for PK: thiamine, ThDP, ThMP, erythrocyte transketolase activity		х		х						х		
Blood Sampling for PrecivityAD2 test which includes Aβ42/ Aβ40 Ratio, p-tau217/np- tau217(p-tau217 Ratio)	Х									х		
Blood Sampling for Biomarkers (total tau, p- tau231, p-tau217, NfL, GFAP)		х								Х		

			STUDY PERIOD								
	Enrollment	Allocation		Post-allocation							nd
Visit Number	1	2	3	4	5	6	7	8	9	10	11
TIMEPOINT	Screening	Baseline	Wk 4	Wk 8	Wk 12	Wk 24	Wk 36	Wk 48	Wk 60	Wk 72	Wk 76
Blood Collection for Biobanking		х						х		х	
Cranial MRI	Х									Х	
Optional Lumbar Puncture for CSF biomarkers & Post-LP Safety Telephone		х								х	
CAGE-AID	Х										
C-SSRS	•										
MMSE	Х										
Neuropsychological Measures (In-Person & Remote)		х				Х		х		х	
NPI		х				х		x		х	
Research Satisfaction Survey		х				Х		x		Х	
IP Accountability			+								
Treatment Blinding Questionnaire										Х	
Telephone Follow-Up											Х

* Abbreviations: ECG - electrocardiogram, TSH - thyroid stimulating hormone, PK - pharmacokinetics, PD - pharmacodynamics, AGE – advanced glycation end products, ThDP - thiamine diphosphate, ThMP - thiamine monophosphate, NFL - Neurofilament light chain, GFAP - Glial Fibrillary Acidic Protein, $A\beta$ - Beta-amyloid, MRI - Magnetic resonance imaging, CSF - Cerebrospinal fluid, LP – lumbar puncture, CAIGE-AID - CAGE Adapted to Include Drugs, C-SSRS – Columbia - Suicide Severity Rating Scale, MoCA – Montreal Cognitive Assessment, MMSE – Mini Mental State Exam, CDR – Clinical Dementia Rating, ADAS-Cog13 - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13, ADCS-ADL-MCI – Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale for use in Mild Cognitive Impairment, , NPI – Neuropsychiatric Inventory, IP - Investigational Product.

